We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
NBIX vs. GRDN: Which Stock Is the Better Value Option?
Read MoreHide Full Article
Investors looking for stocks in the Medical - Drugs sector might want to consider either Neurocrine Biosciences (NBIX - Free Report) or Guardian Pharmacy Services (GRDN - Free Report) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.
Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores work to identify stocks with specific traits.
Right now, Neurocrine Biosciences is sporting a Zacks Rank of #2 (Buy), while Guardian Pharmacy Services has a Zacks Rank of #3 (Hold). This system places an emphasis on companies that have seen positive earnings estimate revisions, so investors should feel comfortable knowing that NBIX is likely seeing its earnings outlook improve to a greater extent. But this is only part of the picture for value investors.
Value investors are also interested in a number of tried-and-true valuation metrics that help show when a company is undervalued at its current share price levels.
Our Value category grades stocks based on a number of key metrics, including the tried-and-true P/E ratio, the P/S ratio, earnings yield, and cash flow per share, as well as a variety of other fundamentals that value investors frequently use.
NBIX currently has a forward P/E ratio of 16.05, while GRDN has a forward P/E of 32.48. We also note that NBIX has a PEG ratio of 0.55. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. GRDN currently has a PEG ratio of 2.00.
Another notable valuation metric for NBIX is its P/B ratio of 4.3. The P/B ratio pits a stock's market value against its book value, which is defined as total assets minus total liabilities. For comparison, GRDN has a P/B of 7.55.
Based on these metrics and many more, NBIX holds a Value grade of B, while GRDN has a Value grade of C.
NBIX stands above GRDN thanks to its solid earnings outlook, and based on these valuation figures, we also feel that NBIX is the superior value option right now.
View the Zacks #1 Rank List
Image: Bigstock
NBIX vs. GRDN: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Drugs sector might want to consider either Neurocrine Biosciences (NBIX - Free Report) or Guardian Pharmacy Services (GRDN - Free Report) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.
Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores work to identify stocks with specific traits.
Right now, Neurocrine Biosciences is sporting a Zacks Rank of #2 (Buy), while Guardian Pharmacy Services has a Zacks Rank of #3 (Hold). This system places an emphasis on companies that have seen positive earnings estimate revisions, so investors should feel comfortable knowing that NBIX is likely seeing its earnings outlook improve to a greater extent. But this is only part of the picture for value investors.
Value investors are also interested in a number of tried-and-true valuation metrics that help show when a company is undervalued at its current share price levels.
Our Value category grades stocks based on a number of key metrics, including the tried-and-true P/E ratio, the P/S ratio, earnings yield, and cash flow per share, as well as a variety of other fundamentals that value investors frequently use.
NBIX currently has a forward P/E ratio of 16.05, while GRDN has a forward P/E of 32.48. We also note that NBIX has a PEG ratio of 0.55. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. GRDN currently has a PEG ratio of 2.00.
Another notable valuation metric for NBIX is its P/B ratio of 4.3. The P/B ratio pits a stock's market value against its book value, which is defined as total assets minus total liabilities. For comparison, GRDN has a P/B of 7.55.
Based on these metrics and many more, NBIX holds a Value grade of B, while GRDN has a Value grade of C.
NBIX stands above GRDN thanks to its solid earnings outlook, and based on these valuation figures, we also feel that NBIX is the superior value option right now.